Olema Oncology is a clinical-stage biopharmaceutical company developing novel therapies to transform treatment for metastatic breast cancer and beyond. Backed by Lightspeed.
About the role
As the Senior Manager, Clinical Supply Integration reporting to the Vice President, Clinical Supply Chain, you will oversee the end-to-end flow of investigational medicinal products (IMPs), from manufacturing through packaging and labeling, QP release, logistics, clinical depots, and trial sites. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Demonstrated experience coordinating end-to-end clinical supply activities across manufacturing, packaging and labeling, release
- Previous exposure to inventory, demand, expiry, logistics, and distribution preferred
- Strong project management and data reconciliation skills, with demonstrated ability to investigate discrepancies and drive issues through resolution
- Strong vendor management and governance experience, including performance monitoring, issue escalation, and resolution
- Oncology clinical trial experience preferred
More about this role
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to...
Browse similar: Startup jobs · San Francisco Bay Area